BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 12376203)

  • 1. Phase I study of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumours.
    Androulakis N; Kouroussis C; Mavroudis D; Kakolyris S; Souglakos J; Agelaki S; Kalbakis K; Malas K; Pallis A; Samonis G; Georgoulias V
    Eur J Cancer; 2002 Oct; 38(15):1992-7. PubMed ID: 12376203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors.
    Mavroudis D; Kouroussis Ch; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Samonis G; Georgoulias V
    Oncology; 2002; 62(3):216-22. PubMed ID: 12065868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weekly paclitaxel combined with pegylated liposomal doxorubicin (CaelyxTM) given every 4 weeks: dose-finding and pharmacokinetic study in patients with advanced solid tumors.
    Briasoulis E; Pentheroudakis G; Karavasilis V; Tzamakou E; Rammou D; Pavlidis N
    Ann Oncol; 2004 Oct; 15(10):1566-73. PubMed ID: 15367419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.
    Rose PG; Greer BE; Horowitz IR; Markman M; Fusco N
    Gynecol Oncol; 2007 Jan; 104(1):114-9. PubMed ID: 16959305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and oxaliplatin in patients with advanced solid tumors.
    Kalbakis K; Pappas P; Kouroussis C; Vamvakas L; Kalykaki A; Vardakis N; Nikolaidou M; Marselos M; Georgoulias V; Mavroudis D
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):449-56. PubMed ID: 17960381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours.
    Bozionelou V; Vamvakas L; Pappas P; Agelaki S; Androulakis N; Kalykaki A; Nikolaidou M; Kentepozidis N; Giassas S; Marselos M; Georgoulias V; Mavroudis D
    Br J Cancer; 2007 Jul; 97(1):43-9. PubMed ID: 17551496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline.
    Hong RL; Lin CH; Chao TY; Kao WY; Wang CH; Hsieh RK; Hwang WS
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):847-53. PubMed ID: 17609947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
    Chen LT; Liu TW; Wu CW; Chung TR; Shiah HS; Jan CM; Liu JM; Whang-Peng J; Chang JY
    Oncology; 2002; 63(3):239-47. PubMed ID: 12381903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dose escalation study of pegylated liposomal Doxorubicin (caelyx) in combination with capecitabine (xeloda) in patients with refractory solid tumors.
    Maltezos E; Amarantidis K; Trichas M; Vasiliadis M; Toromanidou M; Chatzaki E; Karayiannakis A; Tsaroucha A; Romanidis K; Kakolyris S
    Oncology; 2005; 69(6):463-9. PubMed ID: 16374040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (HeCOG).
    Janinis J; Stathopoulos GP; Nikolaidis P; Kalofonos HP; Kalogera-Fountzila A; Samantas E; Aravantinos G; Anagnostopoulos A; Tolis C; Makatsoris T; Rigatos SK; Bafaloukos D; Dimopoulos MA; Daniilidis J; Fountzilas G
    Anticancer Drugs; 2004 Jun; 15(5):479-87. PubMed ID: 15166622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of weekly docetaxel and liposomal doxorubicin in patients with advanced solid tumors.
    Kouroussis Ch; Androulakis N; Vamvakas L; Kalykaki A; Spiridonakou S; Kentepozidis N; Saridaki Z; Xiropoulou E; Georgoulias V
    Oncology; 2005; 69(3):202-7. PubMed ID: 16127289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors.
    Eng C; Mauer AM; Fleming GF; Bertucci D; Rotmensch J; Jacobs RH; Ratain MJ
    Ann Oncol; 2001 Dec; 12(12):1743-7. PubMed ID: 11843253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer.
    Tew WP; Radovich D; O'Reilly E; Schwartz G; Schrag D; Saltz LB; Kelsen DP; Kepler S; Ilson DH
    Invest New Drugs; 2009 Aug; 27(4):366-73. PubMed ID: 18956138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group.
    Gogas H; Papadimitriou C; Kalofonos HP; Bafaloukos D; Fountzilas G; Tsavdaridis D; Anagnostopoulos A; Onyenadum A; Papakostas P; Economopoulos T; Christodoulou C; Kosmidis P; Markopoulos C
    Ann Oncol; 2002 Nov; 13(11):1737-42. PubMed ID: 12419745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer.
    Sparano JA; Malik U; Rajdev L; Sarta C; Hopkins U; Wolff AC
    J Clin Oncol; 2001 Jun; 19(12):3117-25. PubMed ID: 11408509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors.
    Dees EC; O'Neil BH; Lindley CM; Collichio F; Carey LA; Collins J; Riordan WJ; Ivanova A; Esseltine D; Orlowski RZ
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):99-107. PubMed ID: 18327587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A dose escalation study of weekly docetaxel in patients with advanced solid tumors.
    Kouroussis C; Agelaki S; Mavroudis D; Souglakos J; Kakolyris S; Kalbakis K; Vardakis N; Reppa D; Hatzidaki D; Samonis G; Georgoulias V
    Cancer Chemother Pharmacol; 2000; 46(6):488-92. PubMed ID: 11138462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of a weekly schedule of a fixed dose of cisplatin and escalating doses of paclitaxel in patients with advanced oesophageal cancer.
    Polee MB; Verweij J; Siersema PD; Tilanus HW; Splinter TA; Stoter G; Van der Gaast A
    Eur J Cancer; 2002 Jul; 38(11):1495-500. PubMed ID: 12110496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I-II study of pegylated liposomal doxorubicin combined with weekly paclitaxel as first-line treatment in patients with metastatic breast cancer.
    Bourgeois H; Ferru A; Lortholary A; Delozier T; Boisdron-Celle M; Abadie-Lacourtoisie S; Joly F; Chieze S; Chabrun V; Gamelin E; Tourani JM
    Am J Clin Oncol; 2006 Jun; 29(3):267-75. PubMed ID: 16755180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.